Genome-Wide Association Studies of MRI-Defined Brain Infarcts: Meta-Analysis From the CHARGE Consortium * Supplemental Appendix by Debette, S. et al.
Genome-wide Association Studies of MRI-defined Brain Infarcts:
Meta-analysis from the CHARGE Consortium
Stephanie Debette, MD, PhD*, Joshua C. Bis, PhD*, Myriam Fornage, PhD*, Helena
Schmidt, MD, PhD*, M. Arfan Ikram, MD, PhD*, Sigurdur Sigurdsson, MSc*, Gerardo Heiss,
MD, Maksim Struchalin, MSc, Albert V. Smith, PhD, Aad van der Lugt, MD PhD, Charles
DeCarli, MD, Thomas Lumley, PhD, David S. Knopman, MD, Christian Enzinger, MD, Gudny
Eiriksdottir, MSc, Peter J. Koudstaal, MD, PhD, Anita L. DeStefano, PhD, Bruce M. Psaty,
MD, PhD, Carole Dufouil, PhD, Diane J. Catellier, DrPH, Franz Fazekas, MD, Thor Aspelund,
PhD, Yurii S. Aulchenko, PhD, Alexa Beiser, PhD, Jerome I. Rotter, MD, Christophe
Tzourio, MD, PhD, Dean K. Shibata, MD, Maria Tscherner, MD, Tamara B. Harris, MD, MS,
Fernando Rivadeneira, MD, PhD, Larry D. Atwood, PhD, Kenneth Rice, PhD, Rebecca F.
Gottesman, MD, PhD, Mark A. van Buchem, MD, PhD, Andre G. Uitterlinden, PhD, Margaret
Kelly-Hayes, RN DEd, Mary Cushman, MD, MSc, Yicheng Zhu, MD, Eric Boerwinkle, PhD,
Vilmundur Gudnason, MD, PhD, Albert Hofman, MD, PhD, Jose R. Romero, MD, Oscar
Lopez, MD, Cornelia M. van Duijn, PhD, Rhoda Au, PhD, Susan R. Heckbert, MD, PhD,
Philip A. Wolf, MD, Thomas H. Mosley, PhD**, Sudha Seshadri, MD**, Monique M.B.
Breteler, MD, PhD**, Reinhold Schmidt, MD**, Lenore J. Launer, PhD**, and WT Longstreth
Jr, MD, MPH**
Abstract
Background—Previous studies examining genetic associations with MRI-defined brain infarct
have yielded inconsistent findings. We investigated genetic variation underlying covert MRI-
infarct, in persons without histories of transient ischemic attack or stroke. We performed meta-
analysis of genome-wide association studies of white participants in 6 studies comprising the
Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium.
Methods—Using 2.2 million genotyped and imputed SNPs, each study performed cross-
sectional genome-wide association analysis of MRI-infarct using age and sex-adjusted logistic
regression models. Study-specific findings were combined in an inverse-variance weighted meta-
analysis, including 9401 participants with mean age 69.7, 19.4% of whom had ≥1 MRI-infarct.
Results—The most significant association was found with rs2208454 (minor allele frequency:
20%), located in intron 3 of MACRO Domain Containing 2 gene and in the downstream region of
Fibronectin Leucine Rich Transmembrane Protein 3 gene. Each copy of the minor allele was
associated with lower risk of MRI-infarcts: odds ratio=0.76, 95% confidence interval=0.68–0.84,
p=4.64×10−7. Highly suggestive associations (p<1.0×10−5) were also found for 22 other SNPs in
linkage disequilibrium (r2>0.64) with rs2208454. The association with rs2208454 did not replicate
in independent samples of 1822 white and 644 African-American participants, although 4 SNPs
within 200kb from rs2208454 were associated with MRI-infarcts in African-American sample.
Conclusions—This first community-based, genome-wide association study on covert MRI-
infarcts uncovered novel associations. Although replication of the association with top SNP failed,
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possibly due to insufficient power, results in the African American sample are encouraging, and
further efforts at replication are needed.
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Vascular disease of the brain is a leading cause of long-term disability and death. The
burden of brain vascular disease is far greater than suggested by occurrence of acute
neurological events such as stroke.1 Brain imaging techniques, especially magnetic
resonance imaging (MRI), have revealed that brain infarcts are common in the elderly,
especially small subcortical infarcts.2 While the majority of these MRI-infarcts do not
produce acute clinical symptoms leading to a diagnosis of stroke, they cannot be considered
benign, silent, or asymptomatic, as they are associated with an increased risk for cognitive
deficits, motor impairments, and future stroke.2 The pathogenesis of these covert brain
infarcts remains poorly understood.
Whereas several monogenic disorders are known to cause brain infarcts, the genes
underlying brain infarcts in the general population remain undetermined.3 A genetic
component is suggested by increased risk of covert MRI-infarcts among individuals whose
parents or siblings have experienced clinically overt infarcts.4,5 As we will detail, previous
candidate gene studies of covert MRI-infarcts have yielded inconsistent findings. Genome-
wide association studies (GWAS) of MRI-infarcts are lacking and would permit an unbiased
search for genetic variants associated with this phenotype, without relying on a priori
hypotheses about underlying pathophysiology.6
To study genetics of these infarcts, we adapted an analytic approach used in a prior study of
stroke from the Cohorts for Heart and Aging Research in Genomic Epidemiology
(CHARGE) consortium7 and combined GWAS from 6 prospective population-based cohort
studies: the Aging Gene-Environment Susceptibility-Reykjavik Study (AGES-Reykjavik);
the Atherosclerosis Risk in Communities (ARIC) Study; the Austrian Stroke Prevention
Study (ASPS); the Cardiovascular Health Study (CHS); the Framingham Heart Study
(FHS); and the Rotterdam Study. We present results from this meta-analysis that included
9401 stroke-free white participants.
METHODS
Consortium
The CHARGE consortium includes large prospective community-based cohort studies
having genome-wide variation data coupled with extensive data on multiple phenotypes.8
All participating studies agreed on phenotype harmonization, covariate selection, pre-
specified analytic plans for within-study analyses, and meta-analysis of results. Each study
secured approval from institutional review boards, and all participants provided written
informed consent for study participation, MRI scanning, and use of DNA for genetic
research.
Setting
Details of cohort selection, risk factor assessment, and outcome determination in the 6
studies have been reported previously (Appendix, Section 1). Briefly, the AGES-Reykjavik
Study is a single center prospective continuation of the Reykjavik Study, which included
persons born 1907–1935 and living in Reykjavik, Iceland in 1967, when the study was
started. In 2002–2006, 5764 participants from the cohort were reexamined as a part of the
AGES-Reykjavik Study.9 The ARIC study enrolled adults aged 45 and 64 years, from 4
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U.S. communities (N=15,792, including 11,478 whites). The baseline examination was in
1987–1989.10 The ASPS enrolled 2007 inhabitants of Graz, Austria who lacked
neuropsychiatric disease. Between 1991–1994 and 1999–2003, an extended diagnostic
work-up including neuroimaging was done in a subset of participants aged 45 to 85 years.
11,12 The CHS enrolled adults who were 65 years or older and from 4 U.S. communities
(N=5,888 including 4,925 whites). The baseline examination was either in 1989–90 or
1992–93.13 The FHS is a U.S.-based single-site study that comprises 3 generations of
participants. Members of the Original cohort followed since 1948 (N=5,209)14,15 and the
Offspring cohort followed since 1971 (N=5,124),14 were invited to undergo an initial brain
MRI in 1999–2005. The Rotterdam Study enrolled inhabitants from a district of Rotterdam
(Ommoord), The Netherlands, aged 55 years or older (N=7,983) at the baseline examination
in 1990–93 (Rotterdam Study I).16 In 2001, the Rotterdam Study cohort was expanded by
3,011 newly eligible persons (Rotterdam Study II).
MRI scans
In each study, eligible participants were invited to undergo MRI scans, which were
performed and interpreted in a standardized fashion without knowledge of demographic or
clinical information (Appendix, Section 2). Infarct on MRI scan was defined as an area of
abnormal signal intensity in a vascular distribution that lacked mass effect. Infarcts had to be
3–4 millimeters in size or greater. Efforts were made in all studies to distinguish infarcts
from dilated perivascular spaces. All participants were categorized as having or not at least 1
MRI-infarct.
Genotyping
The consortium was formed after individual studies had finalized their GWAS platforms,
which differed across studies. All studies used their genotype data to impute to the 2.5
million non-monomorphic, autosomal SNPs described in HapMap's CEU panel. Extensive
quality control (QC) analyses were performed in each cohort. Because the top SNP was
imputed in all of the cohorts, we directly genotyped it in studies where the quality of
imputation was judged to be poor. Details on the genotyping, imputation, and QC efforts can
be found in the Appendix, Section 3.
Study population
Participants were eligible for these analyses if they had genotyping, an MRI, and lacked a
history of transient ischemic attack or stroke prior to their MRI (covert MRI-infarcts).
Participants were entirely or almost entirely European whites in the AGES-Reykjavik Study,
ASPS, FHS and Rotterdam Study, so African American participants from ARIC and CHS
were not included in these analyses. In addition, CHS did not genotype participants with any
form of clinical cardiovascular disease at baseline. By design, ASPS did not perform MRI
scans in patients with transient ischemic attack or stroke. Also ASPS and Rotterdam Study
did not perform MRI scans in participants with dementia. The number and characteristics of
participants from each cohort are shown in Table 1.
Statistical analyses within studies
Each study fit an additive genetic model with a 1-degree of freedom trend test relating
genotype dosage, 0 to 2 copies of the minor allele, to having or not at least 1 MRI-infarct.
We used logistic regression models to calculate odds ratios (OR) with corresponding 95%
confidence intervals (CI). Initial analyses were adjusted only for age and sex to avoid
adjusting for covariates that might lie along a causal pathway. In addition, ARIC and CHS
also adjusted for study site, and FHS adjusted for familial structure. To explore potential
mechanisms, we additionally adjusted our most significant association in one model for
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systolic blood pressure and in another model for the presence or absence of hypertension,
defined as systolic blood pressure ≥140 mm Hg, diastolic blood pressure ≥90 mm Hg or use
of antihypertensive medications.17 All studies screened for latent population substructure,
which was negligible (Appendix, Section 4).
Meta-analysis
We conducted a fixed-effects meta-analysis of results from the 6 studies, with 7 cohorts
counting the Rotterdam Study II, using inverse-variance weighting. After QC, filtering, and
imputation within each study, we restricted our meta-analysis to 2,217,889 autosomal SNPs
that were common to all studies and had an average minor allele frequency (MAF) greater
than 2%. Details on the meta-analysis strategy and functional annotation of SNPs are
available in the Appendix, Section 5. As suggested by others,6 we decided a priori on a
genome-wide significance threshold of 5×10−8. SNPs with 5×10−8<p<1×10−5 were
considered highly suggestive associations. As available in meta-analysis, we also examined
associations with candidate SNPs, or their proxies, previously reported to be significantly
associated with covert MRI-infarcts.
Replication
We attempted to replicate findings for our top SNP by genotyping it in 1822 elderly white
participants from the 3C-Dijon study18,19 and 644 African American participants from the
ARIC study.10 We also 59 explored SNPs within 300kb of our top SNP using in-silico
replication in the African American sample (Appendix, Section 7).10 We set the threshold
for replication at a one-sided p-value of 0.05.
RESULTS
Among 9401 participants whose mean age was 69.7 years and who were 53.4% women,
1822 (19.4%) had at least 1 MRI-infarct (Table 1). After meta-analysis the genomic inflation
factor lambda was 0.996, indicating no significant inflation of p-values. Figure 1 shows the
genome-wide plot of p-values for individual SNPs against their genomic position. None of
the peaks cleared the threshold for genome-wide significance, but 51 SNPs had highly
suggestive associations with p<1×10–5 (Table 2 and Appendix, Section 6 and Table A).
There was no significant heterogeneity across studies for the association with these SNPs
(Appendix, Section 6).
The most significant association was found on chromosome 20p12 with SNP rs2208454,
located in intron 3 of MACRO Domain Containing 2 (MACROD2) gene and in the
downstream region of Fibronectin Leucine Rich Transmembrane Protein 3 (FLRT3) gene.
The OR for MRI-infarcts was 0.76 (95% CI=0.68–0.84, p=4.64×10−7). Additional
adjustment for systolic blood pressure (OR=0.76, 95% CI=0.68–0.85) or hypertension
(OR=0.76, 95% CI=0.68–0.84) did not change results. Figure 2 shows a forest plot of risk
estimates for rs2208454 across the 7 cohorts. Twenty-two other SNPs in intron 3 of
MACROD2 were also associated with MRI-infarcts with a p-value of less than 1.0×10−5
(Table 2 and Appendix, Table A). All were in linkage disequilibrium with rs2208454:
r2>0.64 for all and r2>0.8 for 17 of the SNPs. Of these 22 SNPs, 1 was intronic within
FLRT3 (rs6110247), and 3 were potential transcription factor binding sites (rs6110247,
rs743216, and rs3789335). Figure 3 shows all SNPs within a 200kb region on either side of
the top hit, together with p-values, recombination rates, and known genes in that region.
Although estimated quality of imputation for rs2208454 was excellent in most studies (O/E
ratio > 0.95), it was poor in CHS (O/E ratio = 0.48). Therefore, rs2208454 was genotyped in
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CHS. When incorporating this result in the meta-analysis instead of the imputed data, the
OR was the same at 0.76 but the p-value smaller at 1.44×10−7.
We failed to replicate findings for the top SNP either in 1822 white participants from 3C-
Dijon for whom mean age was 72.5 years and 9.4% had at least 1 MRI-infarct (MAF=22%,
OR=0.99, 95% CI=0.76–1.29, p=0.92) or in 644 African-American participants from the
ARIC study for whom mean age was 61.5 years and 15.5% had at least 1 MRI-infarct
(MAF=6.5%, OR=1.26, 95% CI=0.74–2.15, p=0.40). However, four other SNPs in intron 3
of MACROD2 within 50–151kb from rs2208454 were significantly associated with MRI-
infarcts in the African-American sample (rs7268327, p=0.045; rs1998237, p=0.006;
rs4464346, p=0.0006; rs8116105, p=0.01). In the discovery sample, rs8116105 was also
associated with MRI-infarcts, although the direction of the association was opposite
(p=0.02) (Appendix, Table B). The linkage disequilibrium pattern in this region differs
substantially between Caucasian and African populations (Figure 4). Details on the
replication effort are contained in the Appendix, Section 7.
We repeated these analyses including, rather than excluding, participants with a history of a
transient ischemic attack or stroke (Table 1). The results were similar although the
associations were slightly weaker, in general (data not shown). We also examined
associations with previously reported candidate SNPs, or their proxies, none of which was
significant after correction for multiple testing (Appendix, Section 9). In addition, we
examined associations with top SNPs in the Ninjurin-2 gene associated with ischemic stroke
in a recent CHARGE GWAS meta-analysis7 and found none significantly associated with
MRI-infarcts. Finally, we explored relations between ischemic stroke and the 23 SNPs in
MACROD2 (Table 2) in the recent CHARGE GWAS meta-analysis on ischemic stroke.7 No
significant association of these SNPs with ischemic stroke was identified.
DISCUSSION
This meta-analysis of GWAS data on covert MRI-defined brain infarcts included 9401
participants without a history of transient ischemic attack or stroke from 6 community-based
studies. The most significant association (p=4.64×10−7) was found for SNP rs2208454 on
chromosome 20p12, located in intron 3 of MACROD2 and in the downstream region of
FLRT3. The less common allele was associated with a lower risk. Twenty-two SNPs in
linkage disequilibrium with rs2208454 were also associated with MRI-infarcts with p-values
less than 1.0×10−5, as were 28 other SNPs in 8 different loci. No association reached our
preset threshold for genome-wide significance of 5.0×10−8. In 2 replication samples of 1822
white participants from 3C-Dijon and 644 African-American participants from ARIC, we
did not observe an association with rs2208454, although 4 SNPs within 200kb from
rs2208454 were associated with MRI-infarcts in the African-American sample. Finally, we
failed to observe an association with SNPs previously reported to be associated significantly
with covert MRI-infarcts in candidate genes studies.
The function of the protein encoded by MACROD2 is poorly understood. It contains a macro
domain that is evolutionarily conserved and expressed in fetal and adult human brain.20,21
Macro domains bind ADP-ribose, suggesting a role in ADP-ribosylation, a post-translational
modification involved in many processes including DNA repair, transcriptional activation
and repression, and telomere and chromatin biology.22 Nested in intron 3 of MACROD2,
FLRT3 encodes fibronectin leucine rich transmembrane protein 3.23 The gene is expressed
in various tissues, including brain, and is well conserved across species.24 The protein it
encodes modulates homotypic cell adhesion and promotes fibroblast growth factor signaling,
24 which is potentially involved in angiogenesis and neurogenesis.25 In animal experiments,
FLRT3 was shown to promote neurite outgrowth after axonal injury.26,27
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Intriguingly, even though both FLTR3 and Ninjurin-2 appear to modulate response to
neuronal injury, the Ninjurin-2 SNPs identified in the recently published ischemic stroke
GWAS within the CHARGE consortium were not significantly associated with covert MRI-
infarcts and the MACROD2 SNPs identified through the present analysis were not
associated with overt ischemic stroke. A possible explanation for this discrepancy could be
that MRI-infarcts comprise mainly small subcortical infarcts, while ischemic stroke
represents a much more heterogeneous entity. Further investigations are needed, beginning
with replication of the associations in external cohorts of MRI-defined infarcts, ischemic
stroke, and subtypes of ischemic stroke.
None of the 23 SNPs in MACROD2 with p<10−5 was significantly associated with gene
expression in publicly available genome-wide expression quantitative trait loci (eQTL)
datasets (Appendix, Section 6), but this finding should be interpreted cautiously as less than
half of these SNPs were present on any of the genotyping arrays used in these studies and
eQTL may be tissue and insult specific.
This meta-analysis has strengths. It included 6 large cohort studies with similar MRI
protocols. The analyses were restricted to white participants to minimize the risk of
population stratification. Genotyping was subjected to rigorous quality control. Our study
also has limitations. Despite having close to 10,000 participants of whom almost 2,000 had
covert MRI-infarcts, we had limited power to detect associations with small effect sizes and
associations with rare variants. An important caution is that the association with the top SNP
was not directly replicated in 2 independent samples. Hence we cannot exclude the
possibility that this association was a chance finding. However, the power to detect an
association with rs2208454 in the 2 replication samples was relatively low: 61% for the
white participants from 3C-Dijon and 18% for the African-American participants from
ARIC, assuming the same effect size as in the discovery sample, which is likely an
overestimation.28 The definition of infarcts may also have differed across discovery and
replication cohorts, especially concerning the discrimination of infarcts from enlarged
perivascular spaces. Furthermore, identified SNPs may not be the causal variants but merely
markers in linkage disequilibrium with causal variants. Substantial differences in linkage
patterns between whites and African-Americans could result in different markers being in
linkage disequilibrium with the causal variant in the 2 populations. Interestingly, 4 SNPs
located in the same locus as rs2208454 were associated with MRI-infarcts in the African-
American sample. Although these exploratory results do not provide direct replication, as
these SNPs were in weak LD with rs2208454, they suggest that the locus may be worthy of
further exploration. If replication can be obtained in the future, including in African
Americans samples, the latter could perhaps help refine the signal and prove useful for the
identification of a causal variant. Finally, even though the studies included in the meta-
analysis are population-based, the samples are not perfectly representative of the total
cohort, as they include subsets of individuals who were able to undergo brain MRI and
agreed to do so.
This meta-analysis of GWAS shows highly suggestive association of covert MRI-infarcts
with rs2208454 on chromosome 20p12 (p=4.64×10−7). Attempted replication of the top
SNP in an independent white sample failed, and additional attempts in larger samples to
replicate this finding, as well as associations with other suggestive loci, are needed.
Extending replication efforts not only in white but also African-American populations may
prove useful for fine mapping purposes. The molecular, clinical, and epidemiological
correlates of confirmed associations may permit new insights into the pathophysiology and
prevention of covert brain infarcts.
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Genome-wide signal intensity (Manhattan) plot showing individual p-values against their
genomic position for covert MRI-defined brain infarcts. Within each chromosome (x-axis),
results are plotted left to right from p-terminal end. Solid black line indicates preset
threshold for genome-wide significance, p=5.0×10−8; dashed blue line, more liberal
threshold for genome-wide significance also used in the literature, p=5.0×10−7; dotted red
line, threshold for highly suggestive associations, p=1.0×10−5.
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Forest plot for top hit (rs2208454). Individual studies are plotted against individual effect
sizes (odds ratios). Size of blue boxes is inversely proportional to variance. Horizontal lines
are 95% confidence intervals.
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Regional plot for associations in region centered on top hit. All SNPs (triangles) are plotted
with their meta-analysis p-values against their genomic position. The color of the triangles
represents the linkage disequilibrium between SNPs: purple: r2≤0.05, light blue:
0.05<r2≤0.10, green: 0.10<r2≤0.30, yellow: 0.30<r2≤0.60, orange: 0.60<r2≤0.80, red:
r2>0.80. Light blue line represents estimated recombination rates. Genes are shown as dark
green arrows.
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Linkage disequilibrium (LD) plot of region in MACROD2 including top hit (rs2208454), 22
other SNPs with p<10−5 in meta-analysis, and 4 SNPs with p<0.05 in African-American
sample, using HapMap release 22. Plot on top depicts LD in European population (CEU)
while plot on bottom depicts LD in African population (YRI). The color scheme is white for
D’<1 and LOD<2, blue for D’=1 and LOD<2, shades of pink and red for D’<1 and LOD≥2,
and bright red for D’=1 and LOD≥2. The SNP marked in red is rs2208454, the 4 SNPs
marked in blue are SNPs with p<0.05 in African-American sample, from left to right:
rs7268327, rs1998237, rs4464346, rs8116105. LD could not be measured for 3 SNPs in the
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YRI population because of a minor allele frequency <0.001 (rs6135125, rs6110247,
rs12624446). Green lines represent genes in region.
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